1
|
Zhang X, Wang T, Zhang Y, Wang F, Chen J, Ni J, Sun R, Wei Z, Zhang G, Li W, Li J, Lu P. Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation. Leuk Lymphoma 2023; 64:2133-2139. [PMID: 37674391 DOI: 10.1080/10428194.2023.2254428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 08/14/2023] [Accepted: 08/16/2023] [Indexed: 09/08/2023]
Abstract
T-acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) patients with t(8;14)(q24;q11)/TCRA/D::MYC translocation represent a rare subgroup, with an aggressive course. In our retrospective analysis of 14 patients, all were identified during refractory or relapsed stages (5 primary tumor, 9 relapse). Notably, extramedullary invasion was detected in most patients. Four exhibited STIL::TAL1 translocation, and six demonstrated CDKN2A/B gene loss. The therapeutic outcomes were notably poor for all seven patients who received only chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT); all eventually succumbed to the disease with a median OS of 3 months. In the application of CD7 CAR-T therapy in six patients, five achieved CR. Of the four patients who underwent HSCT following CAR-T therapy, all have remained disease-free. The prognosis for T-ALL/LBL patients with t(8;14) translocation remains bleak, but interventions involving CD7 CAR-T may offer a potential pathway to CR. HSCT following CAR-T could be a viable strategy for long-term survival.
Collapse
Affiliation(s)
- Xian Zhang
- Hebei Yanda Lu Daopei Hospital, Langfang, P.R. China
- Beijing Lu Daopei Institute of Hematology, Beijing, P.R. China
| | - Tong Wang
- Hebei Yanda Lu Daopei Hospital, Langfang, P.R. China
- Beijing Lu Daopei Institute of Hematology, Beijing, P.R. China
| | - Yang Zhang
- Hebei Yanda Lu Daopei Hospital, Langfang, P.R. China
| | - Fang Wang
- Hebei Yanda Lu Daopei Hospital, Langfang, P.R. China
| | - Jiaqi Chen
- Hebei Yanda Lu Daopei Hospital, Langfang, P.R. China
| | - Jingbo Ni
- Hebei Yanda Lu Daopei Hospital, Langfang, P.R. China
| | - Ruijuan Sun
- Hebei Yanda Lu Daopei Hospital, Langfang, P.R. China
- Beijing Lu Daopei Institute of Hematology, Beijing, P.R. China
| | - Zhijie Wei
- Hebei Yanda Lu Daopei Hospital, Langfang, P.R. China
- Beijing Lu Daopei Institute of Hematology, Beijing, P.R. China
| | - Gailing Zhang
- Hebei Yanda Lu Daopei Hospital, Langfang, P.R. China
| | - Wenqian Li
- Hebei Yanda Lu Daopei Hospital, Langfang, P.R. China
| | - Jingjing Li
- Hebei Yanda Lu Daopei Hospital, Langfang, P.R. China
- Beijing Lu Daopei Institute of Hematology, Beijing, P.R. China
| | - Peihua Lu
- Hebei Yanda Lu Daopei Hospital, Langfang, P.R. China
- Beijing Lu Daopei Institute of Hematology, Beijing, P.R. China
| |
Collapse
|
2
|
T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness. Genes (Basel) 2021; 12:genes12081118. [PMID: 34440292 PMCID: PMC8394887 DOI: 10.3390/genes12081118] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2021] [Revised: 07/17/2021] [Accepted: 07/20/2021] [Indexed: 12/11/2022] Open
Abstract
T-cell acute lymphoblastic leukemias (T-ALL) are immature lymphoid tumors localizing in the bone marrow, mediastinum, central nervous system, and lymphoid organs. They account for 10-15% of pediatric and about 25% of adult acute lymphoblastic leukemia (ALL) cases. It is a widely heterogeneous disease that is caused by the co-occurrence of multiple genetic abnormalities, which are acquired over time, and once accumulated, lead to full-blown leukemia. Recurrently affected genes deregulate pivotal cell processes, such as cycling (CDKN1B, RB1, TP53), signaling transduction (RAS pathway, IL7R/JAK/STAT, PI3K/AKT), epigenetics (PRC2 members, PHF6), and protein translation (RPL10, CNOT3). A remarkable role is played by NOTCH1 and CDKN2A, as they are altered in more than half of the cases. The activation of the NOTCH1 signaling affects thymocyte specification and development, while CDKN2A haploinsufficiency/inactivation, promotes cell cycle progression. Among recurrently involved oncogenes, a major role is exerted by T-cell-specific transcription factors, whose deregulated expression interferes with normal thymocyte development and causes a stage-specific differentiation arrest. Hence, TAL and/or LMO deregulation is typical of T-ALL with a mature phenotype (sCD3 positive) that of TLX1, NKX2-1, or TLX3, of cortical T-ALL (CD1a positive); HOXA and MEF2C are instead over-expressed in subsets of Early T-cell Precursor (ETP; immature phenotype) and early T-ALL. Among immature T-ALL, genomic alterations, that cause BCL11B transcriptional deregulation, identify a specific genetic subgroup. Although comprehensive cytogenetic and molecular studies have shed light on the genetic background of T-ALL, biomarkers are not currently adopted in the diagnostic workup of T-ALL, and only a limited number of studies have assessed their clinical implications. In this review, we will focus on recurrent T-ALL abnormalities that define specific leukemogenic pathways and on oncogenes/oncosuppressors that can serve as diagnostic biomarkers. Moreover, we will discuss how the complex genomic profile of T-ALL can be used to address and test innovative/targeted therapeutic options.
Collapse
|
3
|
Milani G, Matthijssens F, Van Loocke W, Durinck K, Roels J, Peirs S, Thénoz M, Pieters T, Reunes L, Lintermans B, Vandamme N, Lammens T, Van Roy N, Van Nieuwerburgh F, Deforce D, Schwab C, Raimondi S, Dalla Pozza L, Carroll AJ, De Moerloose B, Benoit Y, Goossens S, Berx G, Harrison CJ, Basso G, Cavé H, Sutton R, Asnafi V, Meijerink J, Mullighan C, Loh M, Van Vlierberghe P. Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia. Br J Haematol 2019; 185:169-174. [PMID: 29938777 PMCID: PMC7081658 DOI: 10.1111/bjh.15425] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Gloria Milani
- Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - Filip Matthijssens
- Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - Wouter Van Loocke
- Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - Kaat Durinck
- Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - Juliette Roels
- Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - Sofie Peirs
- Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - Morgan Thénoz
- Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - Tim Pieters
- Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
- Molecular and Cellular Oncology Lab, Department for Biomedical Molecular Biology, Ghent University, Ghent, Belgium
- VIB Inflammation Research Center, Ghent University, Ghent, Belgium
| | - Lindy Reunes
- Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - Beatrice Lintermans
- Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - Niels Vandamme
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
- Molecular and Cellular Oncology Lab, Department for Biomedical Molecular Biology, Ghent University, Ghent, Belgium
- VIB Inflammation Research Center, Ghent University, Ghent, Belgium
| | - Tim Lammens
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
- Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium
| | - Nadine Van Roy
- Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | | | - Dieter Deforce
- Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium
| | - Claire Schwab
- Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
| | - Susana Raimondi
- Department of Pathology and the Hematological Malignancies Program, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
| | - Luciano Dalla Pozza
- The Cancer Centre for Children, The Children’s Hospital, Westmead, Australia
| | | | - Barbara De Moerloose
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
- Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium
| | - Yves Benoit
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
- Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium
| | - Steven Goossens
- Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
- Molecular and Cellular Oncology Lab, Department for Biomedical Molecular Biology, Ghent University, Ghent, Belgium
| | - Geert Berx
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
- Molecular and Cellular Oncology Lab, Department for Biomedical Molecular Biology, Ghent University, Ghent, Belgium
| | - Christine J. Harrison
- Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
| | - Giuseppe Basso
- Women and Child Health Department, Hematology-Oncology Laboratory Istituto di Ricerca Pediatrica (IRP), University of Padova, Padova, Italy
| | - Hélène Cavé
- Department of Genetics, University Hospital of Robert Debré and Paris-Diderot University, Paris, France
| | - Rosemary Sutton
- Children’s Cancer Institute, Lowy Cancer Research Centre UNSW, Sydney, New South Wales, Australia
| | - Vahid Asnafi
- Laboratory of Onco-Hematology, Institut Necker Enfants-Malades, INSERM U1151, Paris, France
| | - Jules Meijerink
- The Máxima Center for Pediatric Oncology/Hematology, Utrecht, the Netherlands
| | - Charles Mullighan
- Department of Pathology and the Hematological Malignancies Program, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
| | - Mignon Loh
- Department of Pediatrics, UCSF Benioff Children’s Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA
| | - Pieter Van Vlierberghe
- Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| |
Collapse
|
4
|
Hu J, Han Q, Gu Y, Ma J, McGrath M, Qiao F, Chen B, Song C, Ge Z. Circular RNA PVT1 expression and its roles in acute lymphoblastic leukemia. Epigenomics 2018; 10:723-732. [PMID: 29693417 DOI: 10.2217/epi-2017-0142] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
AIM The roles of circular RNA PVT1 (circPVT1) are explored in the patients with acute lymphoblastic leukemia (ALL). METHODS The circPVT1 level was detected by qRT-PCR and western blot. The apoptotic cells were examined by the annexin V assay in lentiviral shRNA knockdown cells. RESULTS circPVT1 was highly expressed in ALL compared with normal bone marrow samples. circPVT1 expression was also significantly higher in ALL cell lines. circPVT1 knockdown inhibited cell proliferation and induced cell apoptosis through suppression of its neighbor gene c-Myc, and antiapoptotic Bcl-2 protein expression. CONCLUSION circPVT1 is upregulated in ALL. Silencing circPVT1 results in cell growth arrest and apoptosis of the cells. Our results also suggested a therapeutic potential of targeting circPVT1 in ALL.
Collapse
Affiliation(s)
- Jiaojiao Hu
- Department of Hematology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China
| | - Qi Han
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
| | - Yan Gu
- Department of Hematology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China
| | - Jinlong Ma
- Department of Hematology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China
| | - Mary McGrath
- Department of Pediatrics, Pennsylvania State University Medical College, Hershey, PA 17033, USA
| | - Fengchang Qiao
- Department of Prenatal Diagnosis, State Key Laboratory of Reproductive Medicine, Obstetrics & Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing 210004, China
| | - Baoan Chen
- Department of Hematology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China
| | - Chunhua Song
- Department of Pediatrics, Pennsylvania State University Medical College, Hershey, PA 17033, USA
| | - Zheng Ge
- Department of Hematology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China
| |
Collapse
|
5
|
Skalska-Sadowska J, Dawidowska M, Szarzyńska-Zawadzka B, Jarmuż-Szymczak M, Czerwińska-Rybak J, Machowska L, Derwich K. Translocation t(8;14)(q24;q11) with concurrent PTEN alterations and deletions of STIL/TAL1 and CDKN2A/B in a pediatric case of acute T-lymphoblastic leukemia: A genetic profile associated with adverse prognosis. Pediatr Blood Cancer 2017; 64. [PMID: 27759908 DOI: 10.1002/pbc.26266] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Revised: 08/17/2016] [Accepted: 08/19/2016] [Indexed: 12/28/2022]
Abstract
We report a pediatric case of acute T-lymphoblastic leukemia (T-ALL) with NOTCH1wt , FBXW7wt , STIL/TAL1, and PTEN (exons 2, 3, 4, 5) monoallelic deletions, biallelic CDKN2A/B deletion, and a minor t(8;14)(q24;q11)-positive subclone. Undetectable by a flow cytometric minimal residual disease assay, the t(8;14)(q24;q11) subclone expanded as detected by fluorescence in situ hybridization from 5% at diagnosis to 26% before consolidation and 100% at relapse bearing a monoallelic deletion (exons 2, 3) with a new frameshift mutation of PTEN and the same set of remaining molecular alterations. This case documents an unfavorable prognostic potential of a co-occurrence of this set of molecular genetic events and addresses risk stratification in T-ALL.
Collapse
Affiliation(s)
- Jolanta Skalska-Sadowska
- Department of Pediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznań, Poland
| | | | | | - Małgorzata Jarmuż-Szymczak
- Institute of Human Genetics, Polish Academy of Sciences, Poznań, Poland.,Department of Hematology and Bone Marrow Transplantation, University of Medical Sciences, Poznań, Poland
| | - Joanna Czerwińska-Rybak
- Department of Hematology and Bone Marrow Transplantation, University of Medical Sciences, Poznań, Poland
| | - Ludomiła Machowska
- Department of Pediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznań, Poland
| | - Katarzyna Derwich
- Department of Pediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznań, Poland
| |
Collapse
|